The Competitive Landscape: No Longer a Race
The GLP-1 weight-loss drug market is often framed as a head-to-head race between Eli Lilly and Novo Nordisk, but that framing may no longer be accurate. Over the course of this year, Eli Lilly's competitive advantage has not merely held but has actively strengthened. Despite a number of headwinds — including the arrival of an oral version of Wegovy from Novo Nordisk — the uptake of Lilly's Zepbound has continued to be remarkably strong. Its share of prescriptions is very high, and it has become clear that it is simply the superior product on the market right now. At this point, it is arguably no longer fair to call the competition a "race" at all, given how decisively Lilly has pulled ahead.
The Diversification Playbook: Deploying GLP-1 Profits
A particularly interesting story is what Eli Lilly is doing with the enormous profits generated by the insatiable demand for GLP-1 drugs. Rather than simply sitting on that cash, the company is deploying it to diversify its own portfolio — reallocating capital into acquisitions, including snapping up companies and research efforts in the infectious-disease space.
From a credit-analysis perspective, this playbook is viewed favorably. Credit analysts are, by nature, always focused on the downside, and so any attempt to diversify away from a future loss of exclusivity on a major product is seen as a positive. A blockbuster drug eventually loses patent protection, and building out other revenue streams ahead of that day reduces the risk that the loss creates.
That said, it is still very early in this process. Eli Lilly has an extremely long runway ahead of it, during which it looks set to hold what will probably be the top weight-loss products on the market. That dominance will provide a substantial cash-flow windfall. Exactly what the company will ultimately do with all of that cash remains to be seen, but mergers and acquisitions are expected to be a major use of the funds.
It is worth noting that not all of the cash will go toward diversification. Eli Lilly still has significant manufacturing investments to make in order to support its products — mainly the weight-loss franchise itself. Even so, the cash windfall gives the company a great deal of optionality and strengthens the underlying business over the long term.
Pills Versus Injectables: Expanding the Menu, Not Replacing It
A key question for the next leg of growth is how the oral pills will compete against the injectable versions of these drugs. One of the more fascinating findings from the research is that the pill is able to bring first-time users into the market — people who were previously turned off by the idea of an injection or "jab."
The prevailing view, however, is that pills should be understood as an expansion of the menu rather than a direct competitor to the injectables. At this point, the injectables are simply much more effective. Nevertheless, there will always be a subset of the population that is averse to needles and feels more comfortable taking a pill, and the oral option serves that group.
The specific advantage of Eli Lilly's pill over Novo Nordisk's pill is that Lilly's version is genuinely easy to manufacture. This is significant strategically. The biggest opportunity for the pill is to reach markets where the manufacturing capacity for injectables simply does not exist. Because the pill is so much easier to produce, Lilly could get into those markets first and fastest, gaining access to populations that previously represented no opportunity at all. The pill, in other words, is less a weapon against the injectable and more a key to unlocking entirely new geographic and demographic markets.
Trading Eli Lilly: A Defined-Risk Options Strategy
Turning to how an investor might actually play the stock: Eli Lilly shares were trading lower on the day in question (while peers were higher), but the stock was only about 5% off its recent all-time highs. Given the company's growth numbers and the way it is outcompeting Wegovy and Novo Nordisk's other products, the price-to-earnings multiple on the name has actually come down — the earnings growth has outpaced the share price.
Because this is a very high-priced stock — around $1,100 per share — the options market makes a lot of sense for anyone who wants to express a directional view without committing the capital required to trade the shares outright.
The Trade: A Short Put Vertical
The strategy outlined is a neutral-to-bullish position built as a short put vertical. The mechanics are as follows:
- Expiration: The July 2nd weekly option series was chosen — roughly 17 days to expiration, giving about two and a half weeks in the position.
- Sell the out-of-the-money 1085-strike put.
- Buy the 1065-strike put against it. This long put is purchased specifically to keep the position risk-defined, which is important in a high-priced name like this where an undefined-risk position could be dangerous.
- The result is a short, neutral-to-bullish, $20-wide put vertical.
The Numbers
The position collects roughly a $5 credit. Translated into dollars, that means making about $500 per spread, against roughly $1,500 in risk. The reward is therefore considerably smaller than the risk — a lot of risk relative to the reward — but that unfavorable ratio is offset by a higher probability of success. The short 1085 strike being sold has about a 71% probability of finishing out of the money at expiration.
This structure gives the trade a meaningful cushion to the downside. The break-even point sits at about $1,080, which represents roughly a 4.5% move to the downside before the position begins to lose money. In other words, the stock can fall about four and a half percent and the trade still works; only beyond that break-even does the position start to hurt.
A Practical Caution
One practical warning accompanies the trade: the bid-ask spreads on these options are really wide. Because of that, price discovery is warranted — it is important to work the order carefully and not simply pay the posted prices when executing strategies in a name as high-priced as Eli Lilly.
The overall trade-off, then, is this: an investor can still take a directional bias on the stock — in this case neutral to bullish — while giving themselves a comfortable downside cushion of about 4.5%, aiming to make $500 with $1,500 at risk on a defined-risk, neutral-to-bullish short put vertical.